Accra has turned down a major US health financing package, citing demands for pathogen information, medical records and questionable limits on drug oversight. The decision has ignited a continent-wide conversation about who really controls Africa’s health data.
ACCRA — Ghana has raised a question that reaches far beyond its own health system: what is a nation’s sovereignty worth when foreign aid comes with sensitive strings attached?
Accra’s answer is now clear: not $109 million.
The Ghanaian government declined a new health agreement proposed by the United States, which would have brought roughly $109 million in American funding over five years. The broader package was valued at around $300 million, factoring in complementary contributions expected from Ghana.
President John Dramani Mahama confirmed and explained the rejection during an appearance at the Council on Foreign Relations in New York on September 25.
His words landed hard.
“Who takes the medical records of another country?”
According to the Ghanaian president, the draft agreement would have required Ghana to hand over pathogen profiles and medical data to the United States. He also said the text imposed a counterpart funding obligation on Ghana and contained provisions concerning control over medical products entering the country.
For Mahama, those conditions were simply “humiliating.”
What Washington was actually seeking
The controversy deserves scrutiny beyond the headline-grabbing quote.
Ghana did not reject a $100 million envelope merely because it originated in the United States. The sticking point was the conditions tied to the financing.
Reports in May indicated that the draft agreement, with a total value of about $300 million, would have provided Ghana with approximately $109 million over five years. Arnold Kavaarpuo, executive director of Ghana’s Data Protection Commission and a participant in the negotiations, said certain provisions would have allowed access to sensitive health data under circumstances that could potentially identify individuals. In his view, the scope of that access went well beyond what is normally required.
The BMJ also reported that the Ghanaian proposal envisaged access to health data and pathogens for 16 American companies. The journal noted, however, that several clauses in the new US health agreements remain difficult to examine publicly, since not all negotiated texts have been released.
A nuance is therefore necessary: it would be excessive to claim the United States was demanding unrestricted access to “all Ghanaians’ medical records.” What is documented, instead, are Ghanaian concerns about the extent of access to health data and pathogen information.
Why this data matters so much
Behind medical records lies a genuine question of power.
Health data reveals which diseases are circulating, where they are spreading, which populations are most exposed and how outbreaks are evolving.
Pathogen data can also carry considerable scientific value. It can support research into vaccines, treatments and surveillance of emerging epidemics.
That is precisely what is fueling concerns among several African governments.
In February 2026, Jean Kaseya, director general of the Africa Centres for Disease Control and Prevention (Africa CDC), had already voiced serious concerns about data and pathogen-sharing provisions in the new US health agreements. Some deals required rapid sharing of sensitive data without guaranteeing African countries access to treatments or vaccines that might result from that information.
Ghana is therefore not an isolated case.
Accra no longer wants to depend entirely on foreign aid
The rejection also comes in a particular context.
Since a large portion of US aid programs was suspended, Ghana has been seeking to reduce its reliance on external funding. In February 2025, the Ghanaian presidency already estimated the shortfall caused by the suspension of USAID funding at $156 million, including $78.2 million directly affecting essential health programs.
The Mahama government is now pushing the idea of “health sovereignty.”
This orientation was reinforced in September with the launch of the report A Sovereign Future for Health, presented under the Accra Reset initiative. The document proposes, among other things, reducing Southern countries’ dependence on external financing and strengthening their own health systems.
Accra’s message is therefore relatively clear: Ghana wants to continue working with foreign partners, but on the basis of agreements it considers more balanced.
Another point of friction: medicines
The other element Mahama revealed is particularly sensitive.
According to the president, the draft agreement would have exempted certain medicines and medical products supplied under the program from oversight by Ghana’s Food and Drugs Authority (FDA).
That claim has not been publicly confirmed in detail by the US government, which, when questioned, said it does not comment on the details of bilateral negotiations.
But if that provision indeed matched the text presented to the Ghanaian government, it explains part of Accra’s firmness: for the authorities, health financing should not lead to reducing the national regulator’s ability to control medical products used on its territory.
And the American response?
Washington has not publicly detailed the contested clauses.
A US State Department spokesperson said the United States does not disclose details of bilateral negotiations, while stating that Washington is still looking for ways to strengthen its partnership with Ghana.
This absence of full publication of the text therefore prevents definitive answers to several essential questions.
Exactly what data would have been accessible?
To which American companies or institutions?
Under what circumstances could individuals have been identified?
How long would the data have been retained?
What legal guarantees would have protected Ghanaian patients?
On these points, public information remains incomplete.
Ghana opens a debate that goes beyond Ghana
The real issue in this affair may lie precisely there.
For decades, many African health systems have depended on funding, medicines, equipment and programs from abroad. These partnerships have saved lives and fought major diseases.
But the digital transformation of health is now changing the nature of cooperation.
Aid is no longer only about money, medicines or equipment. It can also provide access to a strategic resource: data.
And Ghana has just reminded the world that it intends to keep control of that resource.
John Mahama says his government rejected the draft after review by the Ministry of Health and its passage through Cabinet. He also says the decision had the support of the entire government and was taken very quickly.
Ghana will now have to demonstrate that it can fill the abandoned funding gap without compromising its health programs.
But for Accra, the choice seems deliberate:
better to seek other partners than to conclude an agreement the government considers incompatible with health sovereignty and the protection of Ghanaians’ data.
The question Ghana is now posing to its foreign partners is simple:
When Africa receives aid to care for its people, must it also surrender control over information about those people?
The debate has probably only just begun.
